Your session is about to expire
← Back to Search
Continuous Glucose Monitoring for Diabetes
N/A
Waitlist Available
Led By Stanislaw Klek
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to month 3 post-discharge
Awards & highlights
Study Summary
This trial will compare the effects of two different methods of managing diabetes.
Who is the study for?
This trial is for adults aged 18-100 with type 1 or type 2 diabetes who are starting insulin treatment at NYU Langone Hospital - Long Island between Sep. 2022 and Aug. 2023. It's not for those who used insulin before admission, are on steroids, or pregnant women.Check my eligibility
What is being tested?
The study compares two methods of monitoring blood sugar in new-to-insulin patients after hospital discharge: wearing a continuous glucose monitor (CGM) for two weeks versus using a traditional blood glucose monitor (BGM). Insulin doses will be adjusted based on the results.See study design
What are the potential side effects?
While the trial itself doesn't involve medications that cause side effects, both CGM and BGM can lead to skin irritation where devices or needles enter the skin, and there may be discomfort from regular finger pricks with BGM.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to month 3 post-discharge
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to month 3 post-discharge
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage Change in Hemoglobin A1c (HbA1c)
Secondary outcome measures
Number of Emergency Department (ER) Visits
Number of Hospital Admissions
Number of Hypoglycemic Events
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Continuous Glucose Monitoring (CGM)Experimental Treatment1 Intervention
Patients in the CGM group will be instructed to wear a CGM uninterruptedly for 2 weeks duration.
Group II: Blood Glucose Monitoring (BGM)Active Control1 Intervention
Patients in the BGM group will be instructed to check their blood glucose utilizing fingerstick glucose monitoring multiple times daily depending on their insulin regimen for 2 weeks duration.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuous Glucose Monitor
2021
Completed Early Phase 1
~860
Find a Location
Who is running the clinical trial?
Abbott Diabetes Care IncUNKNOWN
NYU Langone HealthLead Sponsor
1,367 Previous Clinical Trials
839,641 Total Patients Enrolled
17 Trials studying Diabetes
20,132 Patients Enrolled for Diabetes
Stanislaw KlekPrincipal InvestigatorNYU Langone Hospital - Long Island
1 Previous Clinical Trials
299 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with diabetes.I am currently taking corticosteroids.I use insulin at home before joining the trial.I am starting insulin therapy as I leave the hospital.I am not currently pregnant and understand I will be withdrawn from the study if I become pregnant.I am between 18 and 100 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Blood Glucose Monitoring (BGM)
- Group 2: Continuous Glucose Monitoring (CGM)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who is eligible to enroll in this clinical trial?
"Qualified applicants to this trial must have diabetes, be between 18 and 100 years of age, and the clinic is looking for a total of 120 individuals."
Answered by AI
Is the age limit of this clinical trial restricted to persons aged 40 or older?
"Applicants for this research study should be between 18 and 100 years old."
Answered by AI
Are there any current openings for participants in this experiment?
"This medical trial, which was initially uploaded to clinicaltrials.gov on January 1st 2023 and edited up until November 21st 2022, is no longer seeking participants. Fortunately, there are 177 other trials open for recruitment at present time."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger